Ultragenyx Pharmaceutical
RARE
RARE
165 hedge funds and large institutions have $2.5B invested in Ultragenyx Pharmaceutical in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 39 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
165
Holders Change
+2
Holders Change %
+1.23%
% of All Funds
3.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
70
Reduced
39
Closed
21
Calls
$1.04M
Puts
$9.62M
Net Calls
-$8.59M
Net Calls Change
-$5.42M
Top Buyers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$59.2M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$47.4M |
| 3 |
ClearBridge Investments
New York
|
+$40.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.8M |
| 5 |
BlackRock
New York
|
+$25.4M |
Top Sellers
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$12.9M |
| 3 |
Legal & General Group
London,
United Kingdom
|
-$6.73M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
-$5.83M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$4.41M |
